ArticleTherapeutic advances in urology2009
Prospective pharmacologic therapies for the overactive bladder.
Article in Therapeutic advances in urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Efficacy and Safety of Mirabegron in Frail Older Adults with Overactive Bladder.Drugs & aging · 2026Review
- Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women.Scientific reports · 2023Article
- Updates of Overactive Bladder in Pediatrics.International neurourology journal · 2023Article
- Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB).Pharmaceuticals (Basel, Switzerland) · 2023Article
- Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.Investigative and clinical urology · 2021Observational
- Attenuated regulatory function of the small-conductance CaInternational urology and nephrology · 2020Article
- Are there relevant animal models to set research priorities in LUTD? ICI-RS 2019.Neurourology and urodynamics · 2020Review
- Effect of high-fat diet-induced obesity on the small-conductance CaInternational urology and nephrology · 2019Article
- OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.Drugs & aging · 2016Review
- Does hypercholesterolemia affect the relaxation of the detrusor smooth muscle in rats? In vitro and in vivo studies.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Mixed urinary incontinence: what first?Current urology reports · 2015Review
- Mirabegron: a Beta-3 agonist for overactive bladder.The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists · 2014Review
- An animal study to compare the degree of the suppressive effects on the afferent pathways of micturition between tamsulosin and sildenafil.Journal of biomedical science · 2013Article
- Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.International journal of clinical practice · 2013Article
- Sex differences in the physiology and pharmacology of the lower urinary tract.Current urology · 2013Review
- Combination pharmacological therapies for the management of benign prostatic hyperplasia.Drugs & aging · 2012Review
- How to choose appropriate medication for overactive bladder: Findings from the largest integrated clinical trial database analysis of mirabegron studies.Tzu chi medical journalReview
- Avanafil Inhibits the Contractility of the Isolated Caprine Detrusor Muscle.International journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower urinary tract symptoms (LUTS), overactive bladder syndrome (OAB) and detrusor overactivity (DO) are all conditions that can have major effects on quality of life and social functioning. Antimuscarinic drugs are first-line treatment-they often have good initial response rates, but adverse effects and decreasing efficacy cause long-term compliance problems, and alternatives are needed. The recognition of the functional contribution of the urothelium, the spontaneous myocyte activity during bladder filling, and the diversity of nerve transmitters has sparked interest in both peripheral and central modulation of LUTS/OAB/DO pathophysiology. There may be several new possibilities to treat LUTS/OAB/DO. β(3)-AR agonists (YM178), PDE 5 inhibitors (sildenafil, tadalafil, vardenafil), vitamin D analogs (elocalcitol), combinations (α(1)-AR antagonist + antimuscarinic), and drugs with a central mode of action (tramadol, aprepitant) all have Randomized controlled trial (RCT) documented efficacy. Which of these therapeutic principles will be developed to clinically useful treatments remains to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.